A THERAPEUTIC RESEARCH IN THE PATIENTS WITH ESTROGEN RECEPTOR EXPRESSING TUMOR USING POSITRON EMISSION TOMOGRAPHY

题目：激素治疗对雌激素受体表达肿瘤患者的影响：一项正电子发射断层扫描研究[摘要]我们使用fdg和fes为基础的正电子发射断层扫描（PET）研究激素治疗对雌激素受体表达肿瘤患者的影响。在FDG- pet试验中，FDG积累与雌激素受体表达无关，但与所研究的9例乳腺癌患者的肿瘤大小相关。在6例复发性恶性黑色素瘤患者中，FDG积累与DAC-Tam联合雌激素受体阻滞剂他莫昔芬化疗方案的效果无关。接下来，我们评估了3例乳腺癌患者FES-PET检查结果与治疗效果之间的相关性。在所有三个病例中，雌激素受体在原发部位表达，并且所有患者都有多个转移部位。在两个病例中，每个转移部位的FES积累是不同的；在脑转移瘤中观察到更多的FES积累，而在骨转移瘤中没有观察到积累。在一名没有FES积累的骨转移患者中，激素治疗无效，并在6个月后导致更严重的骨转移。研究提示，即使雌激素受体在同一原发部位表达，激素治疗的效果也可能因转移部位而异。在一个病例中，FES在所有转移部位都有高积累，激素治疗是有效的。一年后，该患者的肿瘤标志物st439几乎恢复正常。我们研究了两例乳腺癌FES-PET和FDG-PET的相关性。在两例患者的所有转移部位均观察到FDG积累；然而，激素治疗在一个fes阳性病例中有效，而在另一个fes阴性病例中无效。综上所述，FES-PET而非FDG-PET可能有助于预测激素治疗的效果。需要更多患者的进一步检查来明确FES-PET的作用。少

Title: EFFECTS OF HORMONE THERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-EXPRESSINGTUMORS: A STUDY USING POSITRON EMISSION TOMOGRAPHY[Summary]We studied the effects of hormone therapy in patients with estrogenreceptor-expressing tumors using FDG-and FES-based positron emission tomography (PET). In the FDG-PET trials, FDG accumulation did not correlate with estrogen receptor expression, but did correlate with tumor size in the 9 breast cancer patients studied. In the 6 recurrent malignant melanoma patients, FDG accumulation did not correlate with the effects of the DAC-Tam method, which was the chemotherapy protocol combined with the estrogen blocker tamoxifen.Next, we evaluated the correlation between FES-PET findings and the therapeutic effect in three breast cancer patients. In all three cases, estrogen receptors were expressed in the primary sites and all patients had multiple metastatic sites. In two cases, the FES accumulation was different for each metastatic site; for example, high … More FES accumulation was observed in brain metastases, but no accumulation was observed in bone metastases. In one bone metastases patient without FES accumulation, hormone therapy was not effective, and resulted in much more advanced bone metastases after six months. It was suggested that the effects of hormone therapy may differ according to metastatic site, even if estrogen receptors are expressed at the same primary site. In one case with high FES accumulation in all metastatic sites, hormone therapy was effective. After one year, tumor marker ST 439 was almost normalized in this patient. We investigated the correlation between FES-PET findings and FDG-PET findings in two cases of breast cancer.FDG accumulation was observed in all metastatic sites in both patients; however, hormone therapy was effective in the one FES-positive case but not in the other FES-negative case.In conclusion, it appeared that FES-PET but not FDG-PET may be useful to predict the effects of hormone therapy. Further examinations with larger numbers of patients are required to clarify the role of FES-PET. Less